Showing results (1211-1220 of 1,229) with videos related to

Sort By:
Pageof 123
Nature Communications|March 14, 2025
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trialJacob J Orme, Henan Zhang, Prashanth Lingamaneni, et al.
Frontiers in Digital Health|April 11, 2025
Interactive Panel Summaries of the 2024 Voice AI SymposiumJean-Christophe Bélisle-Pipon, James Anibal, Ruth Bahr, et al.
Nature Medicine|July 7, 2026
Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trialDeborah A Theodore, Bryan T Mayer, Charlotte-Paige Rolle, et al.
MMWR. Morbidity and Mortality Weekly Report|June 6, 2024
Cases of Meningococcal Disease Associated with Travel to Saudi Arabia for Umrah Pilgrimage - United States, United Kingdom, and France, 2024Madhura S Vachon, Anne-Sophie Barret, Jay Lucidarme, et al.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2025
Comparative Safety of Second-Line Antihyperglycemic Agents in Older Adults with Type 2 Diabetes: A Multinational Real-World Evidence From LEGEND-T2DMChungsoo Kim, Fan Bu, Clair Blacketer, et al.
Nature Communications|April 4, 2026
Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetesChungsoo Kim, Fan Bu, Clair Blacketer, et al.
BMJ Open Diabetes Research & Care|November 5, 2025
Semaglutide and diabetic retinopathy: an OHDSI network studyCindy Xinji Cai, Akihiko Nishimura, Sally Baxter, et al.
Ophthalmology|June 2, 2026
Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network StudyCindy X Cai, Brian Toy, Benjamin Martin, et al.
BMJ Medicine|October 13, 2023
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Lovedeep Singh Dhingra, Arya Aminorroaya, et al.
Journal of the American College of Cardiology|August 28, 2024
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DMRohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, et al.
Pageof 123